Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
Phase 1/2 Study of anti-KRAS G12V mTCR Cells, a Targeted KRAS G12V TCR-T Therapy
National Cancer Institute is evaluating safety and tumor response of anti-KRAS G12V mTCR cells given with chemotherapy and cytokine treatment in adults with metastatic NSCLC, gastric, pancreatic, and colorectal…
NCT03190941 - New trial
Multiple solid tumors
Phase 1/2a PTT-936 Trial of ALPK1 Activator in Solid Tumors
This study evaluates the safety, dosage, and efficacy of PTT-936, an ALPK1 activator, administered weekly as monotherapy or with anti-PD-1/L1 every three weeks. It enrolls patients with locally advanced or metastatic…
NCT06244992 - New trial
Multiple solid tumors
Phase 1/2 study of LY3537982, a KRAS G12C inhibitor, in advanced solid tumors.
This open-label trial, sponsored by Eli Lilly and Company, evaluates LY3537982 alone or with agents like pembrolizumab in patients with unresectable advanced or metastatic solid tumors harboring KRAS G12C mutations,…
NCT04956640 - New trial
Multiple solid tumors
Phase 1 FIH XB010, a 5T4-targeted tubulin inhibitor ADC
This dose-escalation and expansion study evaluates the safety, pharmacokinetics, immunogenicity, and preliminary antitumor activity of XB010 as a single agent or with pembrolizumab in patients with locally advanced…
NCT06545331 - New trial
Multiple solid tumors
Phase 1 VT3989 Transcription Factor Inhibitor Trial
This multi-center, open-label study evaluates VT3989 given alone or with immunotherapy (nivolumab/ipilimumab) or targeted therapy (osimertinib) in patients with advanced or metastatic mesothelioma and solid tumors…
NCT04665206 - New trial
Multiple solid tumors
Phase 1b/2 Trial of STC-15, a METTL3 inhibitor
This open-label, non-randomized, multi-cohort study evaluates the safety, tolerability, and antitumor activity of STC-15 plus toripalimab in advanced NSCLC, melanoma, endometrial, and head and neck cancers after…
NCT06975293 - New trial
Multiple solid tumors
Phase 1 trial of BMS-986500, undisclosed target inhibitor in advanced cancers.
This first-in-human study by Bristol-Myers Squibb evaluates BMS-986500 as monotherapy or combined with palbociclib and fulvestrant in advanced solid tumors, including ovarian cancer with CCNE1 amplification and…
NCT06997029 - New trial
Multiple solid tumors
Phase I trial of ulixertinib, an ERK1/2 inhibitor, with palbociclib, a CDK4/6 inhibitor.
This phase I open-label study by UNC Lineberger evaluates safety, MTD, and RP2D of ulixertinib plus palbociclib in patients with advanced solid tumors and refractory melanoma. The trial includes dose escalation and…
NCT03454035 - New trial
Multiple solid tumors
Phase 1 PF-08046037 TLR7 agonist ADC study in advanced malignancies.
Pfizer is evaluating PF-08046037 as monotherapy or with sasanlimab in an open-label trial enrolling patients with advanced NSCLC, HNSCC, melanoma, or PDAC. The study will assess safety, dosing, and initial efficacy…
NCT06974734 - New trial
Multiple solid tumors
Phase I ATLCAR.CD30.CCR4: CAR‑T cells targeting CD30 with CCR4‑mediated tumor homing
This study evaluates ATLCAR.CD30.CCR4 therapy—administered alone or with ATLCAR.CD30 cells—to determine safe dosing in patients with relapsed/refractory CD30+ lymphomas (including Hodgkin, Grey Zone, and T‑cell…
NCT03602157 - New trial
Multiple solid tumors
Phase 2 MDX-1105 PD-L1 mAb trial
Investigators at UPMC are assessing whether discontinuing PD-L1 inhibitor therapy after one year maintains disease stability in patients with advanced solid tumors. The randomized study includes multiple tumor types…
NCT04157985 - New trial
Multiple solid tumors
Phase I IDOV-Immune oncolytic virus trial in advanced solid tumors
This Phase I, open-label, multi-center study by ViroMissile, Inc. is evaluating IDOV-Immune, an oncolytic vaccinia virus therapy, administered as a single IV infusion in adults with advanced, treatment-resistant…
NCT06910657 - New trial
Multiple solid tumors
Phase 1/2 study of YH42946, EGFR and HER2 (+ex20) inhibitor small molecule
YH42946-101 is a first-in-human, open-label, multicenter study from Yuhan Corporation evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity via dose escalation to determine the maximum tolerated…
NCT06616766 - New trial
Multiple solid tumors
Phase III pCSI Proton Beam Therapy for Precise CNS Leptomeningeal Targeting
This Phase III randomized trial by NRG Oncology compares proton craniospinal irradiation with standard involved-field radiotherapy for patients with leptomeningeal metastasis from breast or non-small cell lung…
NCT06500481 - New trial
Non-small cell lung cancer
Phase II alectinib ALK kinase inhibitor trial in resectable NSCLC
This multicenter study sponsored by Hoffmann-La Roche evaluates the safety and efficacy of adjuvant and perioperative alectinib combined with platinum-based chemotherapy in patients with resectable Stage II–IIIB…
NCT06624059 - New trial
Non-small cell lung cancer
Phase 1b/2 trial: cemiplimab (PD-1 inhibitor) with investigational anti-TIM3, anti-CD73, and anti-NKG2A antibodies
This multicenter, open-label study by Servier Bio-Innovation LLC evaluates cemiplimab combined with novel agents in adult patients with untreated advanced/metastatic NSCLC with high PD-L1 expression. The trial…
NCT06162572 - New trial
Non-small cell lung cancer
Phase Ib/II Trial of AB248 Plus Rilvegostomig, a Tigit and PD-1 Bispecific mAb
This open-label, multicenter platform study evaluates safety and efficacy of AB248 with rilvegostomig, alone or with standard chemotherapy, in patients with metastatic non-small cell lung cancer (PD-L1 ≥1%). It aims…
NCT06996782 - New trial
Non-small cell lung cancer
Phase 2 trial: Patritumab Deruxtecan, a HER3-directed antibody-drug conjugate with Pembrolizumab.
This umbrella study investigates adding investigational agents to pembrolizumab with or without platinum-based chemotherapy in treatment-naïve patients with stage IV NSCLC. Evaluating safety and efficacy in…
NCT06731907 - New trial
Non-small cell lung cancer
Phase II/III trial of cemiplimab PD-1 inhibitor in advanced NSCLC.
This randomized study compares adding cemiplimab to docetaxel and ramucirumab versus standard therapy in patients with stage IV or recurrent non-small cell lung cancer after platinum-based chemotherapy and…
NCT06616584 - New trial
Non-small cell lung cancer
Phase 2 PORT modulator "PORTight": a ctDNA-guided adjuvant radiation enhancer for NSCLC.
This Phase 2 single‐arm trial by Rutgers assesses whether postoperative ctDNA positivity can effectively guide adjuvant treatment decisions—including radiation therapy, chemotherapy, immunotherapy, or targeted…
NCT06979661 - New trial
Non-small cell lung cancer
Phase 3 RMC-6236 pan-KRAS inhibitor in RAS-mutated NSCLC
This Phase 3 trial compares safety and efficacy of RMC-6236 versus docetaxel in patients with advanced non‐small cell lung cancer harboring RAS mutations after prior treatment. Sponsored by Revolution Medicines,…
NCT06881784 - New trial
Small cell lung cancer
Phase 2 Tarlatamab Trial: DLL3 and CD3-directed bispecific antibody
This open-label randomized study evaluates Tarlatamab dosing regimens in patients with relapsed or refractory small cell lung cancer. Conducted at global centers by Amgen, it examines the antitumor activity of this…
NCT06745323 - New trial
Breast cancer
Phase 3 EG1206A HER2 mAb vs. Perjeta: Neoadjuvant Breast Cancer Trial
This study compares the efficacy and safety of EG1206A versus Perjeta in combination with trastuzumab and chemotherapy as neoadjuvant and adjuvant treatments for HER2-positive, hormone receptor–negative early breast…
NCT06884254 - New trial
Multiple myeloma
Phase 2 trial: Elranatamab, a BCMA/CD3 bispecific mAb in combination for multiple myeloma
This phase 2 study evaluates Elranatamab with lenalidomide and dexamethasone as first-line therapy in newly diagnosed multiple myeloma patients at University of Miami. The trial compares this ERd combination against…
NCT06997081 - New trial
Multiple myeloma
Phase 1b/2a Study of Mezigdomide Cereblon E3 Ligase Modulator & Elranatamab BCMA/CD3 Bispecific
Celgene sponsors this multicenter, open‐label trial evaluating mezigdomide with elranatamab (plus dexamethasone) to establish the recommended dose and safety in relapsed/refractory multiple myeloma across 2nd–5th…
NCT06988488 - New trial
Multiple myeloma
Phase 2 trial of talquetamab, a GPRC5D x CD3 bispecific antibody, in multiple myeloma.
This trial evaluates a response-adaptive consolidation strategy where MRD-positive patients after frontline induction receive talquetamab, with a switch to teclistamab if MRD negativity is not achieved. The study,…
NCT06993675 - New trial
Colorectal cancer
Phase 1b HRX215 MKK4 inhibitor trial for post-hepatectomy metastatic colorectal cancer
This double-blind, randomized, placebo-controlled trial assesses the safety and pharmacokinetics of HRX215 in adults following liver surgery for metastatic colorectal cancer. Eligible participants include those…
NCT06638502 - New trial
Colorectal cancer
Phase 2 Leronlimab, a CCR5-directed mAb in relapsed microsatellite stable colorectal cancer.
This open-label, randomized, multi-center study evaluates two Leronlimab doses combined with trifluridine-tipiracil plus bevacizumab in patients with CCR5-positive metastatic colorectal cancer who progressed on prior…
NCT06699836 - New trial
Head and neck cancer
Phase Ib/II trial of NT219, an IRS1/2 and STAT3 inhibitor
This study evaluates fixed-dose NT219 combined with pembrolizumab or cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Conducted by University of Colorado, Denver, it enrolls…
NCT06919666 - New trial
Head and neck cancer
Phase I Decitabine DNA-methyltransferase inhibitor trial in surgically resectable HPV-negative head and neck cancer
This Phase I trial at Mayo Clinic evaluates the safety, dose tolerance, and potential efficacy of decitabine when given before standard-of-care surgery followed by radiation and chemotherapy. It enrolls patients with…
NCT06997094
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.